EPZM Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jan 1970 @ 01:00):

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States...

Stats
Dagens volum	0.00
Gjennomsnittsvolum	4.18M
Markedsverdi	0.00
EPS	$-0.210 ( 2022-08-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.704
ATR14	$0.0490 (3.33%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-12	Giordano Michael F	Sell	8 994	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	13 060	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	8 994	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	3 380 951	Common Stock, par value $0.0001
2022-08-12	Conroy Kevin T	Sell	53 324	Common Stock, par value $0.0001

INSIDER POWER
-89.09
Last 98 transactions
Buy: 31 679 726 \| Sell: 42 571 145

Volum Korrelasjon

Lang: 0.22 (neutral)

Kort: -0.56 (weak negative)

Signal:(61.298) Neutral

Epizyme Inc Korrelasjon

10 Mest positive korrelasjoner
APOP	0.959
RMRM	0.951
MEIP	0.933
REAL	0.932
PCVX	0.93
NNOX	0.927
TYHT	0.925
CVGI	0.922
JFU	0.921
PRTA	0.921

10 Mest negative korrelasjoner
XMTR	-0.948
ASTR	-0.938
INFI	-0.922
HRZN	-0.922
UPLD	-0.921
DTEA	-0.92
OM	-0.92
VNET	-0.916
LUNG	-0.914
IRWD	-0.913

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Epizyme Inc Korrelasjon - Valuta/Råvare

0.48
( neutral )

0.54
( weak )

-0.10
( neutral )

0.27
( neutral )

-0.55
( weak negative )

0.12
( neutral )

Epizyme Inc Økonomi

Annual	2021
Omsetning:	$37.43M
Bruttogevinst:	$26.93M (71.95 %)
EPS:	$-2.45

FY	2021
Omsetning:	$37.43M
Bruttogevinst:	$26.93M (71.95 %)
EPS:	$-2.45

FY	2020
Omsetning:	$15.76M
Bruttogevinst:	$10.70M (67.85 %)
EPS:	$-2.29

FY	2019
Omsetning:	$23.80M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Epizyme Inc

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..